多发性硬化症治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球多发性硬化症治疗市场估值约255 亿美元。一种慢性自体免疫疾病）的一系列治疗和药物。这种情况会导致髓鞘（神经纤维的保护层）恶化，扰乱大脑和身体之间的沟通。

多发性硬化症患病率的增加极大地推动了市场的成长。例如，世界卫生组织 (WHO) 报告称，全球有超过 280 万人受到多发性硬化症的影响，其中年轻人和女性更容易受到影响。这种不断上升的盛行率扩大了对有效治疗方法的需求，推动了针对不断扩大的患者群体的创新治疗方法的研究和开发。

多发性硬化症药物开发的最新进展显着增强了疾病管理。在过去的十年中，新疗法在满足不同患者需求方面表现出了卓越的功效。这些进步正在重塑治疗格局，引入有针对性的、便利的、个人化的选择，不仅改善患者的治疗结果，也提高他们的生活品质。

整个产业分为药品类别、给药途径、配销通路和地区。

市场将药物类别分为免疫抑制剂、免疫刺激剂、免疫调节剂、皮质类固醇等。预测显示，到 2032 年，免疫调节剂市场将达到 236 亿美元。它们调节免疫反应，从而降低復发频率和严重程度，减少神经系统恶化事件，并增强整体疾病管理。

市场区隔基于口服和注射剂的给药途径。注射剂又分为肌肉注射、皮下注射和静脉注射。口服药物在 2023 年创造了 149 亿美元的收入。它们使患者能够在家中自我管理，无需医疗监督，从而提高他们的生活品质。

在美国，多发性硬化症治疗市场预计到 2032 年将达到 133 亿美元。美国国家多发性硬化症协会的数据强调了这一点，并指出，2019 年，美国有近 100 万人被诊断出来，这增加了对先进疗法的需求并推动了市场创新。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 多发性硬化症患病率增加
    • 药物开发的进展
    • 日益关注个人化医疗
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 药品成本高
    • 与药物相关的副作用
• 成长潜力分析
• 技术景观
• 管道分析
• 监管环境
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 免疫抑制剂
• 免疫增强剂
• 免疫调节剂
• 皮质类固醇
• 其他药物类别

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 口服
• 注射剂
  • 肌肉注射
  • 皮下
  • 静脉

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbvie Inc.
• Amgen Inc.
• Acorda Therapeutics, Inc.
• Biogen Inc.
• Bayer AG
• Bristol-Myers Squibb Company.
• F. Hoffman-La Roche Ltd
• Johnson and Johnson
• Merck and Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceuticals Company Limited.
• Pfizer Inc.
• Sanofi
• Viatris Inc.

The Global Multiple Sclerosis Therapeutic Market was valued at approximately USD 25.5 billion in 2023. Projections indicate a growth rate of 4.7% CAGR from 2024 to 2032. Multiple sclerosis therapeutics refer to a range of treatments and medications aimed at managing multiple sclerosis, a chronic autoimmune disorder impacting the central nervous system (CNS). This condition deteriorates the myelin sheath, which is the nerve fibers' protective covering, disrupting communication between the brain and body.

The increasing prevalence of multiple sclerosis significantly propels the market growth. For example, the World Health Organization (WHO) reports that over 2.8 million individuals globally are affected by multiple sclerosis, with young adults and females being more susceptible. This rising prevalence amplifies the demand for effective therapeutics, fueling research and development for innovative treatments catering to this expanding patient base.

Recent advancements in drug development for multiple sclerosis have markedly enhanced disease management. In the last decade, new therapies have showcased superior efficacy for catering to diverse patient needs. Such advancements are reshaping the treatment landscape, introducing targeted, convenient, and personalized options that not only improve patient outcomes but also elevate their quality of life.

The overall industry is divided into drug class, route of administration, distribution channel, and region.

The market categorizes drug classes into immunosuppressants, immunostimulants, immunomodulators, corticosteroids, and others. Forecasts suggest the immunomodulators segment will hit USD 23.6 billion by 2032. Immunomodulators, including interferon beta and glatiramer acetate, play a pivotal role in managing multiple sclerosis. They modulate the immune response, leading to reduced relapse frequency and severity, fewer neurological deterioration episodes, and enhanced overall disease management.

The market segments based on administration routes into oral and injectables. The injectables further divide into intramuscular, subcutaneous, and intravenous. The oral segment generated USD 14.9 billion in 2023. Oral medications, being more user-friendly than injectables, boost patient compliance. They empower patients to self-administer at home, free from medical supervision, thus enhancing their quality of life.

In the U.S., the multiple sclerosis therapeutic market is set to reach USD 13.3 billion by 2032. The country's high multiple sclerosis prevalence significantly fuels this market growth. Data from the National Multiple Sclerosis Society highlights this, noting that in 2019, nearly 1 million individuals in the U.S. were diagnosed, intensifying the demand for advanced therapies and driving market innovation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of multiple sclerosis
    • 3.2.1.2 Advancements in drug development
    • 3.2.1.3 Growing focus on personalized medicine
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of the drugs
    • 3.2.2.2 Side effects associated with the medication
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Immunosuppressants
• 5.3 Immunostimulants
• 5.4 Immunomodulators
• 5.5 Corticosteroids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectables
  • 6.3.1 Intramuscular
  • 6.3.2 Subcutaneous
  • 6.3.3 Intravenous

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbvie Inc.
• 9.2 Amgen Inc.
• 9.3 Acorda Therapeutics, Inc.
• 9.4 Biogen Inc.
• 9.5 Bayer AG
• 9.6 Bristol-Myers Squibb Company.
• 9.7 F. Hoffman-La Roche Ltd
• 9.8 Johnson and Johnson
• 9.9 Merck and Co., Inc.
• 9.10 Novartis AG
• 9.11 Teva Pharmaceutical Industries Ltd.
• 9.12 Takeda Pharmaceuticals Company Limited.
• 9.13 Pfizer Inc.
• 9.14 Sanofi
• 9.15 Viatris Inc.